US 11,986,482 B2
Method of promoting antitumor or anti-cancer immunity
Jianbo Yue, Kowloon (HK); Qingru Zhang, Kowloon (HK); Zuodong Ye, Kowloon (HK); and Wang Peng, Kowloon (HK)
Assigned to City University of Hong Kong, Kowloon (HK); and 6J Biotechnology (Hong Kong) Limited, Shatin (HK)
Filed by City University of Hong Kong, Kowloon (HK); and 6J Biotechnology (Hong Kong) Limited, Shatin (HK)
Filed on Mar. 21, 2022, as Appl. No. 17/699,693.
Claims priority of provisional application 63/163,221, filed on Mar. 19, 2021.
Prior Publication US 2022/0305022 A1, Sep. 29, 2022
Int. Cl. A61P 35/00 (2006.01); A61K 31/5377 (2006.01); A61K 39/395 (2006.01)
CPC A61K 31/5377 (2013.01) [A61K 39/3955 (2013.01); A61P 35/00 (2018.01)] 25 Claims
 
1. A method of inhibiting endosomal trafficking of PD-L1, comprising the step of administering a compound of Formula I to a cancer or tumor cell:

OG Complex Work Unit Chemistry
wherein R1 is selected from the group consisting of a hydrogen atom, a halogen atom and a halogenated group;
R2 is selected from the group consisting of

OG Complex Work Unit Chemistry
R3 is a hydrogen atom or

OG Complex Work Unit Chemistry
and
L is a linker group, —(CH2)n—, where n is an integer from 0-5.